AAAAAA

   
Results: 1-25 | 26-42
Results: 1-25/42
A STUDY OF FILGRASTIM (RG-CSF) PRIMING OF ETOPOSIDE CISPLATIN IN ADVANCED NONSMALL CELL LUNG-CANCER/
Authors: MEHDI SA PERRY MC HERNDON JE CRAWFORD J YOUNG R GRAZIANO SL
Citation: Sa. Mehdi et al., A STUDY OF FILGRASTIM (RG-CSF) PRIMING OF ETOPOSIDE CISPLATIN IN ADVANCED NONSMALL CELL LUNG-CANCER/, Journal of interferon & cytokine research, 18(8), 1998, pp. 623-627
COMPARISON OF PSYCHOSOCIAL ADAPTATION OF ADVANCED-STAGE HODGKINS-DISEASE AND ACUTE-LEUKEMIA SURVIVORS
Authors: KORNBLITH AB HERNDON JE ZUCKERMAN E CELLA DF CHERIN E WOLCHOK S WEISS RB DIEHL LF HENDERSON H COOPER MR SCHIFFER C CANELLOS GP MAYER RJ SILVER RT SCHILLING A PETERSON BA GREENBERG D HOLLAND JC
Citation: Ab. Kornblith et al., COMPARISON OF PSYCHOSOCIAL ADAPTATION OF ADVANCED-STAGE HODGKINS-DISEASE AND ACUTE-LEUKEMIA SURVIVORS, Annals of oncology, 9(3), 1998, pp. 297-306
THORACIC RADIATION-THERAPY ADDED TO CHEMOTHERAPY FOR SMALL-CELL LUNG-CANCER - AN UPDATE OF CANCER AND LEUKEMIA GROUP-B STUDY-8083
Authors: PERRY MC HERNDON JE EATON WL GREEN MR
Citation: Mc. Perry et al., THORACIC RADIATION-THERAPY ADDED TO CHEMOTHERAPY FOR SMALL-CELL LUNG-CANCER - AN UPDATE OF CANCER AND LEUKEMIA GROUP-B STUDY-8083, Journal of clinical oncology, 16(7), 1998, pp. 2466-2467
MOLECULAR PATHOLOGICAL SUBSTAGING IN 244 STAGE-I NON-SMALL-CELL LUNG-CANCER PATIENTS - CLINICAL IMPLICATIONS
Authors: KWIATKOWSKI DJ HARPOLE DH GODLESKI J HERNDON JE SHIEH DB RICHARDS W BLANCO R XU HJ STRAUSS GM SUGARBAKER DJ
Citation: Dj. Kwiatkowski et al., MOLECULAR PATHOLOGICAL SUBSTAGING IN 244 STAGE-I NON-SMALL-CELL LUNG-CANCER PATIENTS - CLINICAL IMPLICATIONS, Journal of clinical oncology, 16(7), 1998, pp. 2468-2477
IODINE-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OFPATIENTS WITH RECURRENT MALIGNANT GLIOMAS - PHASE-I TRIAL RESULTS
Authors: BIGNER DD BROWN MT FRIEDMAN AH COLEMAN RE AKABANI G FRIEDMAN HS THORSTAD WL MCLENDON RE BIGNER SH ZHAO XG PEGRAM CN WIKSTRAND CJ HERNDON JE VICK NA PALEOLOGOS N COKGOR I PROVENZALE JM ZALUTSKY MR
Citation: Dd. Bigner et al., IODINE-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OFPATIENTS WITH RECURRENT MALIGNANT GLIOMAS - PHASE-I TRIAL RESULTS, Journal of clinical oncology, 16(6), 1998, pp. 2202-2212
PHASE-I STUDY TO DETERMINE THE MAXIMUM-TOLERATED DOSE OF RADIATION INSTANDARD DAILY AND HYPERFRACTIONATED-ACCELERATED TWICE-DAILY RADIATION SCHEDULES WITH CONCURRENT CHEMOTHERAPY FOR LIMITED-STAGE SMALL-CELL LUNG-CANCER
Authors: CHOI NC HERNDON JE ROSENMAN J CAREY RW CHUNG CT BERNARD S LEONE L SEAGREN S GREEN M
Citation: Nc. Choi et al., PHASE-I STUDY TO DETERMINE THE MAXIMUM-TOLERATED DOSE OF RADIATION INSTANDARD DAILY AND HYPERFRACTIONATED-ACCELERATED TWICE-DAILY RADIATION SCHEDULES WITH CONCURRENT CHEMOTHERAPY FOR LIMITED-STAGE SMALL-CELL LUNG-CANCER, Journal of clinical oncology, 16(11), 1998, pp. 3528-3536
PHASE-I TRIAL OF O-6-BENZYLGUANINE FOR PATIENTS UNDERGOING SURGERY FOR MALIGNANT GLIOMA
Authors: FRIEDMAN HS KOKKINAKIS DM PLUDA J FRIEDMAN AH COKGOR I HAGLUND MM ASHLEY DM RICH J DOLAN ME PEGG AE MOSCHEL RC MCLENDON RE KERBY T HERNDON JE BIGNER DD SCHOLD SC
Citation: Hs. Friedman et al., PHASE-I TRIAL OF O-6-BENZYLGUANINE FOR PATIENTS UNDERGOING SURGERY FOR MALIGNANT GLIOMA, Journal of clinical oncology, 16(11), 1998, pp. 3570-3575
TOXICITY, PHARMACOLOGY AND FEASIBILITY OF ADMINISTRATION OF PEG-L-ASPARAGINASE AS CONSOLIDATION THERAPY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA
Authors: GRAHAM ML ASSELIN BL HERNDON JE CASEY JR CHAFFEE S CIOCCI GH DAESCHNER CW DAVIS AR GOLD S HALPERIN EC LAUGHLIN MJ MARTIN PL OLSON JF KURTZBERG J
Citation: Ml. Graham et al., TOXICITY, PHARMACOLOGY AND FEASIBILITY OF ADMINISTRATION OF PEG-L-ASPARAGINASE AS CONSOLIDATION THERAPY IN PATIENTS UNDERGOING BONE-MARROW TRANSPLANTATION FOR ACUTE LYMPHOBLASTIC-LEUKEMIA, Bone marrow transplantation, 21(9), 1998, pp. 879-885
A DESIGN ALTERNATIVE FOR 2-STAGE, PHASE-II, MULTICENTER CANCER CLINICAL-TRIALS
Authors: HERNDON JE
Citation: Je. Herndon, A DESIGN ALTERNATIVE FOR 2-STAGE, PHASE-II, MULTICENTER CANCER CLINICAL-TRIALS, Controlled clinical trials, 19(5), 1998, pp. 440-450
ANALYSIS OF NEUROENDOCRINE MARKERS, HER2 AND CEA BEFORE AND AFTER CHEMOTHERAPY IN PATIENTS WITH STAGE IIIA NONSMALL CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
Authors: GRAZIANO SL KERN JA HERNDON JE TATUM A BRISSON ML MEMOLI V SUGARBAKER D SKARIN AT KREISMAN H GREEN MR
Citation: Sl. Graziano et al., ANALYSIS OF NEUROENDOCRINE MARKERS, HER2 AND CEA BEFORE AND AFTER CHEMOTHERAPY IN PATIENTS WITH STAGE IIIA NONSMALL CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY, Lung cancer, 21(3), 1998, pp. 203-211
RESULTS OF A PHASE-I TRIAL OF PATIENTS WITH RECURRENT BRAIN-TUMORS AND PRIOR RADIATION-THERAPY TREATED WITH I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 VIA SURGICALLY CREATED RESECTION CAVITIES
Authors: COKGOR I AKABANI G BROWN MT FRIEDMAN AH COLEMAN RE FRIEDMAN HS THORSTAD WL MCLENDON RE BIGNER SH ZHAO XG PEGRAM CN WIKSTRAND CJ HERNDON JE VICK NA PALEOLOGOS N ZALUTSKY MR BIGNER DD
Citation: I. Cokgor et al., RESULTS OF A PHASE-I TRIAL OF PATIENTS WITH RECURRENT BRAIN-TUMORS AND PRIOR RADIATION-THERAPY TREATED WITH I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 VIA SURGICALLY CREATED RESECTION CAVITIES, Neurology, 50(4), 1998, pp. 52005-52005
FACTORS PREDICTIVE OF SURVIVAL AMONG 337 PATIENTS WITH MESOTHELIOMA TREATED BETWEEN 1984 AND 1994 BY THE CANCER AND LEUKEMIA GROUP-B
Authors: HERNDON JE GREEN MR CHAHINIAN AP CORSON JM SUZUKI Y VOGELZANG NJ
Citation: Je. Herndon et al., FACTORS PREDICTIVE OF SURVIVAL AMONG 337 PATIENTS WITH MESOTHELIOMA TREATED BETWEEN 1984 AND 1994 BY THE CANCER AND LEUKEMIA GROUP-B, Chest, 113(3), 1998, pp. 723-731
DIHYDRO-5-AZACYTIDINE AND CISPLATIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA - A PHASE-II STUDY BY THE CANCER AND LEUKEMIA GROUP-B
Authors: SAMUELS BL HERNDON JE HARMON DC CAREY R AISNER J CORSON JM SUZUKI Y GREEN MR VOGELZANG NJ
Citation: Bl. Samuels et al., DIHYDRO-5-AZACYTIDINE AND CISPLATIN IN THE TREATMENT OF MALIGNANT MESOTHELIOMA - A PHASE-II STUDY BY THE CANCER AND LEUKEMIA GROUP-B, Cancer, 82(8), 1998, pp. 1578-1584
HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN PATIENTS WITH RECURRENT AND HIGH-RISK PEDIATRIC BRAIN-TUMORS
Authors: GRAHAM ML HERNDON JE CASEY JR CHAFFEE S CIOCCI GH KRISCHER JP KURTZBERG J LAUGHLIN MJ LONGEE DC OLSON JF PALEOLOGUS N PENNINGTON CN FRIEDMAN HS
Citation: Ml. Graham et al., HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE IN PATIENTS WITH RECURRENT AND HIGH-RISK PEDIATRIC BRAIN-TUMORS, Journal of clinical oncology, 15(5), 1997, pp. 1814-1823
RANDOMIZED TRIAL OF CHEMOTHERAPY AND RADIATION-THERAPY WITH OR WITHOUT WARFARIN FOR LIMITED-STAGE SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY
Authors: MAURER LH HERNDON JE HOLLIS DR AISNER J CAREY RW SKARIN AT PERRY MC EATON WL ZACHARSKI LL HAMMOND S GREEN MR
Citation: Lh. Maurer et al., RANDOMIZED TRIAL OF CHEMOTHERAPY AND RADIATION-THERAPY WITH OR WITHOUT WARFARIN FOR LIMITED-STAGE SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY, Journal of clinical oncology, 15(11), 1997, pp. 3378-3387
PHASE-I TRIAL OF ETOPOSIDE, CARBOPLATIN, AND GM-CSF IN EXTENSIVE SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY (CALGB-8832)
Authors: LUIKART SD HERNDON JE HOLLIS DR MACDONALD M MAURER LH CRAWFORD J CLAMON GH WRIGHT J PERRY MC OZER H GREEN MR
Citation: Sd. Luikart et al., PHASE-I TRIAL OF ETOPOSIDE, CARBOPLATIN, AND GM-CSF IN EXTENSIVE SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY (CALGB-8832), American journal of clinical oncology, 20(1), 1997, pp. 24-30
A LONGITUDINAL-STUDY OF QUALITY-OF-LIFE IN ADVANCED NONSMALL CELL LUNG-CANCER - CANCER AND LEUKEMIA GROUP-B (CALGB)-8931
Authors: HERNDON JE FLEISHMAN S KOSTY MP GREEN MR
Citation: Je. Herndon et al., A LONGITUDINAL-STUDY OF QUALITY-OF-LIFE IN ADVANCED NONSMALL CELL LUNG-CANCER - CANCER AND LEUKEMIA GROUP-B (CALGB)-8931, Controlled clinical trials, 18(4), 1997, pp. 286-300
QUALITY-OF-LIFE FOR ADULT LEUKEMIA SURVIVORS TREATED ON CLINICAL-TRIALS OF CANCER AND LEUKEMIA GROUP-B DURING THE PERIOD 1971-1988 - PREDICTORS FOR LATER PSYCHOLOGIC DISTRESS
Authors: GREENBERG DB KORNBLITH AB HERNDON JE ZUCKERMAN E SCHIFFER CA WEISS RB MAYER RJ WOLCHOK SM HOLLAND JC
Citation: Db. Greenberg et al., QUALITY-OF-LIFE FOR ADULT LEUKEMIA SURVIVORS TREATED ON CLINICAL-TRIALS OF CANCER AND LEUKEMIA GROUP-B DURING THE PERIOD 1971-1988 - PREDICTORS FOR LATER PSYCHOLOGIC DISTRESS, Cancer, 80(10), 1997, pp. 1936-1944
DIHYDRO-5-AZACYTIDINE IN MALIGNANT MESOTHELIOMA - A PHASE-II TRIAL DEMONSTRATING ACTIVITY ACCOMPANIED BY CARDIAC TOXICITY
Authors: VOGELZANG NJ HERNDON JE CIRRINCIONE C HARMON DC ANTMAN KH CORSON JM SUZUKI Y CITRON ML GREEN MR
Citation: Nj. Vogelzang et al., DIHYDRO-5-AZACYTIDINE IN MALIGNANT MESOTHELIOMA - A PHASE-II TRIAL DEMONSTRATING ACTIVITY ACCOMPANIED BY CARDIAC TOXICITY, Cancer, 79(11), 1997, pp. 2237-2242
INTRATHECAL I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OF PATIENTS WITH LEPTOMENINGEAL NEOPLASMS OR PRIMARY BRAIN-TUMOR RESECTION CAVITIES WITH SUBARACHNOID COMMUNICATION - PHASE-I TRIAL RESULTS
Authors: BROWN MT COLEMAN RE FRIEDMAN AH FRIEDMAN HS MCLENDON RE REIMAN R FELSBERG GJ TIEN RD BIGNER SH ZALUTSKY MR ZHAO XG WIKSTRAND CJ PEGRAM CN HERNDON JE VICK NA PALEOLOGOS N FREDERICKS RK SCHOLD SC BIGNER DD
Citation: Mt. Brown et al., INTRATHECAL I-131-LABELED ANTITENASCIN MONOCLONAL-ANTIBODY 81C6 TREATMENT OF PATIENTS WITH LEPTOMENINGEAL NEOPLASMS OR PRIMARY BRAIN-TUMOR RESECTION CAVITIES WITH SUBARACHNOID COMMUNICATION - PHASE-I TRIAL RESULTS, Clinical cancer research, 2(6), 1996, pp. 963-972
A PHASE I II TRIAL OF ETOPOSIDE AND CISPLATIN IN EXTENSIVE SMALL-CELLLUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY/
Authors: MITCHELL EP PERRY MC LUIKART SD CIRRINCIONE CT VANECHO DA HERNDON JE MAURER LH CLAMON G GREEN MR
Citation: Ep. Mitchell et al., A PHASE I II TRIAL OF ETOPOSIDE AND CISPLATIN IN EXTENSIVE SMALL-CELLLUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY/, Lung cancer, 15(2), 1996, pp. 215-223
A RANDOMIZED PHASE-II STUDY OF IFOSFAMIDE MESNA/CISPLATIN PLUS G-CSF OR ETOPOSIDE/CISPLATIN PLUS G-CSF IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY/
Authors: GRAZIANO SL VALONE FH HERNDON JE CRAWFORD J RICHARDS F REGE VB CLAMON G GREEN MR
Citation: Sl. Graziano et al., A RANDOMIZED PHASE-II STUDY OF IFOSFAMIDE MESNA/CISPLATIN PLUS G-CSF OR ETOPOSIDE/CISPLATIN PLUS G-CSF IN ADVANCED NON-SMALL-CELL LUNG-CANCER - A CANCER AND LEUKEMIA GROUP-B STUDY/, Lung cancer, 14(2-3), 1996, pp. 315-329
ANGIOGENESIS AND MOLECULAR BIOLOGIC SUBSTAGING IN PATIENTS WITH STAGE-I NON-SMALL-CELL LUNG-CANCER
Authors: HARPOLE DH RICHARDS WG HERNDON JE SUGARBAKER DJ
Citation: Dh. Harpole et al., ANGIOGENESIS AND MOLECULAR BIOLOGIC SUBSTAGING IN PATIENTS WITH STAGE-I NON-SMALL-CELL LUNG-CANCER, The Annals of thoracic surgery, 61(5), 1996, pp. 1470-1476
LOCALIZED ADENOCARCINOMA OF THE LUNG - ONCOGENE EXPRESSION OF ERBB-2 AND P53 IN 150 PATIENTS
Authors: HARPOLE DH MARKS JR RICHARDS WG HERNDON JE SUGARBAKER DJ
Citation: Dh. Harpole et al., LOCALIZED ADENOCARCINOMA OF THE LUNG - ONCOGENE EXPRESSION OF ERBB-2 AND P53 IN 150 PATIENTS, Clinical cancer research, 1(6), 1995, pp. 659-664
EFFICACY OF COMPARTMENTAL ADMINISTRATION OF IMMUNOTOXIN LMB-1 (B3-LYSPE38) IN A RAT MODEL OF CARCINOMATOUS MENINGITIS
Authors: BIGNER DD ARCHER GE MCLENDON RE FRIEDMAN HS FUCHS HE PAI LH HERNDON JE PASTAN IH
Citation: Dd. Bigner et al., EFFICACY OF COMPARTMENTAL ADMINISTRATION OF IMMUNOTOXIN LMB-1 (B3-LYSPE38) IN A RAT MODEL OF CARCINOMATOUS MENINGITIS, Clinical cancer research, 1(12), 1995, pp. 1545-1555
Risultati: 1-25 | 26-42